Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

  title={Global Consensus Position Statement on the Use of Testosterone Therapy for Women.},
  author={Susan R. Davis and Rodney Baber and Nick Panay and Johannes Bitzer and Sonia Cerdas Perez and Rakibul M. Islam and Andrew M. Kaunitz and Sheryl A Kingsberg and Irene Lambrinoudaki and James H. Liu and Sharon J. Parish and JoAnn V. Pinkerton and Janice M. Rymer and James A. Simon and Linda Vignozzi and Margaret E. Wierman},
  journal={The journal of sexual medicine},
  volume={16 9},
This Statement is being simultaneously published in the journals Climacteric, Maturitas, Journal of Sexual Medicine, and Journal of Clinical Endocrinology and Metabolism on behalf of the International Menopause Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, and The Endocrine Society, respectively. This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause… 
4 Citations
Testosterone Therapy in Women: A Clinical Challenge.
The physiology of testosterone as a normal female hormone in reproductive years and beyond is poorly taught and understood. This has led to unregulated and dangerous prescribing practices by
3rd Annual Meeting of the Androgen Society March 12–14, 2021Virtual Event
  • Androgens: Clinical Research and Therapeutics
  • 2021
Testosterone and Female Sexual Desire: Direct or Indirect Effects?
  • Noel N Kim
  • Medicine
    The journal of sexual medicine
  • 2021


Sexual well-being after menopause: An International Menopause Society White Paper
The process of care for female sexual well-being following menopause is reviewed, from initially approaching the discussion of FSD, to identifying clinical signs and symptoms, and ultimately determining the best available biopsychosocial therapies.
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women
In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence‐based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments.
Androgen levels in adult females: changes with age, menopause, and oophorectomy.
It is reported that serum androgen levels decline steeply in the early reproductive years and do not vary because of natural menopause and that the postmenopausal ovary appears to be an ongoing site of testosterone production.
Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III.
The revision of the ISSWSH nomenclature regarding the criteria for the 2 arousal categories, FCAD and FGAD, and the recommended diagnostic strategies offers a framework for management of women with arousal disorders.
Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II.
A unified set of definitions for female sexual dysfunctions that reflect current science provide useful nomenclature for current and future management of women with sexual disorders and development of new therapies.
Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.
Evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, and the biological and psychological factors are artificially separated for review purposes.
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data.
Testosterone is effective for postmenopausal women with low sexual desire causing distress, with administration via non-oral routes (eg, transdermal application) preferred because of a neutral lipid profile.
Toward excellence in testosterone testing: a consensus statement.
To ensure highly accurate testosterone testing that will result in improved diagnosis, treatment, and prevention of disease through the use of standardized assays, a series of recommendations were agreed upon.
Circulating androgen levels and self-reported sexual function in women.
No single androgen level is predictive of low female sexual function, and the majority of women with low dehydroepiandrosterone sulfate levels did not have low sexual function.
Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.
Evidence warranting low confidence suggests that DHEA administration does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.